SPYRE THERAPEUTICS INC.
NASDAQ: SYRE (Spyre Therapeutics, Inc.)
Last update: 20 hours ago69.42
-5.03 (-6.76%)
| Previous Close | 74.45 |
| Open | 74.09 |
| Volume | 1,429,103 |
| Avg. Volume (3M) | 1,029,082 |
| Market Cap | 5,988,124,672 |
| Price / Sales | 650.22 |
| Price / Book | 3.22 |
| 52 Weeks Range | |
| Earnings Date | 5 May 2026 |
| Diluted EPS (TTM) | -3.06 |
| Total Debt/Equity (MRQ) | 0.06% |
| Current Ratio (MRQ) | 8.06 |
| Operating Cash Flow (TTM) | -169.86 M |
| Levered Free Cash Flow (TTM) | -68.57 M |
| Return on Assets (TTM) | -25.34% |
| Return on Equity (TTM) | -65.82% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Spyre Therapeutics, Inc. | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | -3.5 |
| Insider Activity | NA |
| Price Volatility | -5.0 |
| Technical Moving Averages | 1.5 |
| Technical Oscillators | 4.0 |
| Average | -0.75 |
|
Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 8.71% |
| % Held by Institutions | 106.07% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Commodore Capital Lp | 31 Dec 2025 | 2,388,245 |
| Tcg Crossover Management, Llc | 31 Dec 2025 | 1,900,582 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 70.00 (BTIG, 0.84%) | Buy |
| Median | 60.00 (-13.57%) | |
| Low | 50.00 (Wells Fargo, -27.98%) | Buy |
| Average | 60.00 (-13.57%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 43.21 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| BTIG | 20 Feb 2026 | 70.00 (0.84%) | Buy | 43.21 |
| Wells Fargo | 20 Feb 2026 | 50.00 (-27.97%) | Buy | 43.21 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 06 Feb 2026 | Announcement | Spyre Therapeutics Announces Grants of Inducement Awards |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |